Immix Biopharma, Inc. IMMX Increase (Decrease) in Income Taxes Receivable
Increase (Decrease) in Income Taxes Receivable at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInIncomeTaxesReceivable.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable?
- Immix Biopharma, Inc. (IMMX) reported increase (decrease) in income taxes receivable of $725 in Q1 2026.
- How has Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable changed year-over-year?
- Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable increased by 100.0% year-over-year, from -$2M to $725.
- What is the long-term trend for Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable?
- Over 3 years (2021 to 2025), Immix Biopharma, Inc.'s increase (decrease) in income taxes receivable has grown at a 176.3% compound annual growth rate (CAGR), from -$97.67K to -$2.06M.